Oncology Current Deferred Revenue from 2010 to 2024
| TOIIW Stock | USD 0.02 0 37.70% |
Current Deferred Revenue | First Reported 2010-12-31 | Previous Quarter 545 K | Current Value 517.8 K | Quarterly Volatility 1.2 M |
Check Oncology Institute financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Oncology Institute's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.8 M, Interest Expense of 7.1 M or Selling General Administrative of 67.6 M, as well as many indicators such as Price To Sales Ratio of 0.44, Dividend Yield of 0.0235 or PTB Ratio of 2.51. Oncology financial statements analysis is a perfect complement when working with Oncology Institute Valuation or Volatility modules.
Oncology | Current Deferred Revenue |
Latest Oncology Institute's Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of The Oncology Institute over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Oncology Institute's Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Oncology Institute's overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
Oncology Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 2,664,183 | |
| Geometric Mean | 2,186,429 | |
| Coefficient Of Variation | 46.34 | |
| Mean Deviation | 1,048,398 | |
| Median | 3,379,000 | |
| Standard Deviation | 1,234,586 | |
| Sample Variance | 1.5T | |
| Range | 2.9M | |
| R-Value | (0.77) | |
| Mean Square Error | 672.7B | |
| R-Squared | 0.59 | |
| Significance | 0.0008 | |
| Slope | (212,074) | |
| Total Sum of Squares | 21.3T |
Oncology Current Deferred Revenue History
About Oncology Institute Financial Statements
Oncology Institute investors use historical fundamental indicators, such as Oncology Institute's Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Oncology Institute. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 545 K | 517.8 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Oncology Stock Analysis
When running Oncology Institute's price analysis, check to measure Oncology Institute's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncology Institute is operating at the current time. Most of Oncology Institute's value examination focuses on studying past and present price action to predict the probability of Oncology Institute's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncology Institute's price. Additionally, you may evaluate how the addition of Oncology Institute to your portfolios can decrease your overall portfolio volatility.